Support, Monitoring, and Reminder Technology for Mild Dementia (SMART4MD) for People With Mild Cognitive Impairment and Their Informal Caregivers: Cost-Effectiveness Analysis

Clinical Snapshot

Key Findings

• P Value: Not reported

• Effect Size: Mixed results: Sweden showed higher costs with lower QALYs; Spain showed higher costs with higher QALYs

• Primary Outcome: Incremental cost-effectiveness ratio (ICER) for SMART4MD intervention

• Nnt Or Sensitivity: ICER of €78,000/QALY for Swedish informal caregivers

• Confidence Interval: Not reported

Clinical Application

Moderate - requires tablet technology access and digital literacy among elderly population Relevant to Australian aged care sector; ICER exceeds PBAC cost-effectiveness thresholds (A$45,000-75,000/QALY); may not qualify for PBS subsidisation People with mild cognitive impairment and their informal caregivers in developed healthcare systems

Abstract

BACKGROUND: Support, Monitoring, and Reminder Technology for Mild Dementia (SMART4MD), a customized tablet app, was developed to improve or maintain the quality of life of people with mild cognitive impairment (MCI) and their informal caregivers. OBJECTIVE: This study conducts an 18-month economic evaluation of the SMART4MD app, in addition to standard care, compared with standard care alone in Sweden and Spain, from a health care provider perspective. METHODS: In a pragmatic randomized controlled trial, people with MCI and their informal caregivers were randomized to the intervention and control groups. Health care costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were measured in 345 Swedish people with MCI and their informal caregivers, and in 347 Spanish people with MCI. RESULTS: The analysis showed higher incremental costs and lower QALYs for Swedish people with MCI than for controls, whereas higher incremental costs and higher QALYs were observed for Spanish people with MCI. The intervention was not found to be cost-effective for Swedish informal caregivers, with an ICER of €78,000/QALY (€1=US $1.16). CONCLUSIONS: The differing findings regarding cost-effectiveness for people with MCI in Sweden and Spain highlight the need for further research with extended follow-up, ideally involving a larger sample size and conducted across different national contexts. TRIAL REGISTRATION: ClinicalTrials.gov NCT03325699; https://clinicaltrials.gov/ct2/show/NCT03325699.

References

1. 1.Ghani, Z., Jarl, J., Anderberg, P., Sanmartin Berglund, J., Aparicio, M. Q., Barnestein-Fonseca, P., Cellek, S., Mayoral-Cleries, F., Garolera, M., Guerrero-Pertiñez, G., Hayden, K., Moore, C., Zhang, J., Trepel, D., & Saha, S. (2026). Support, Monitoring, and Reminder Technology for Mild Dementia (SMART4MD) for People With Mild Cognitive Impairment and Their Informal Caregivers: Cost-Effectiveness Analysis. JMIR Human Factors. https://doi.org/10.2196/77808